MERCK Serono

Merck Serono, we have an enduring commitment and focus in our core specialist therapeutic areas of oncology, neurodegenerative diseases, fertility and endocrinology, along with rheumatology as an emerging area of expertise. We also provide a portfolio of cardiometabolic care products, especially in emerging markets where patient need remains high.
Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize our prescription medicines, available in over 150 countries. We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline.
Each year we devote over 1 billion euros, or around 20% of total revenues, to discover and develop breakthrough solutions.
Our expertise in both biotechnology and pharmaceutical chemistry, combined with a profound understanding of disease in our focus therapeutic areas, enables us to take a flexible approach to finding the right compound to treat a specific disease. The capability to develop and manufacture new molecular entities of either type with equal success allows Merck Serono to exploit the full potential of the biological and chemical spheres at every stage of the drug development process.
We truly believe that our focused expertise can make a real difference to people living with serious diseases. Not everything we do leads to a breakthrough, but we never lose sight of the human need that motivates us.

HISTORY
Since we created Merck Serono in 2007, we’ve built a strong, successful business with a reputation for pushing the boundaries of medical science. Today, our bright future as a biopharmaceutical leader owes a great deal to our proud past.
Our story began when the German chemical and pharmaceutical group Merck acquired Serono, the Swiss-based biotechnology leader, integrating two companies with a total of over 400 years of experience in drug-making.
Merck KGaA has a history dating back to 1668, when Friedrich Jacob Merck acquired the Engel Apotheke (“Angel pharmacy”) in Darmstadt, Germany. Serono’s roots as a pioneer in the use of recombinant DNA technology go back to Italy in the early 1900’s.